Drug and Device Companies Offer Recommendations for FDA’s Combo Product Policy Council
By Zachary Brennan -
Published 17 April 2017
Johnson & Johnson (J&J), Allergan, Pfizer and industry group BIO’s suggestions to the US Food and Drug Administration’s (FDA) new Combination Product Policy Council released Monday build on efforts included in the 21st Century Cures Act and the new user fee agreements.
Categories: News, US, FDA, Biologics and biotechnology, Combination products, Drugs, Government affairs, Manufacturing, Medical Devices, Regulatory intelligence, Regulatory strategy
Tags: J&J, Pfizer, Allergan, combination products and FDA